TGFB1 and cancer: Despite being an obvious therapeutic target to prevent the transition from early stage EMT to complete EMT, there is likely limited clinical benefit following targeting of TGFβ1 in cancer due to the high probability of on-target toxicities due to the complexities of TGF signaling and function within the immune system.